Stem definition | Drug id | CAS RN |
---|---|---|
1552 | 75706-12-6 |
Dose | Unit | Route |
---|---|---|
20 | mg | O |
Property | Value | Reference |
---|---|---|
BA (Bioavailability) | 80 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 2 | Benet LZ, Broccatelli F, Oprea TI |
MRTD (Maximum Recommended Therapeutic Daily Dose) | 1.23 ยตM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
EoM (Fraction excreted unchanged in urine) | 1 % | Benet LZ, Broccatelli F, Oprea TI |
S (Water solubility) | 0.02 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
fu (Fraction unbound in plasma) | 0.00 % | Kawashima H, Watanabe R, Esaki T, Kuroda M, Nagao C, Natsume-Kitatani Y, Ohashi R, Komura H, Mizuguchi K |
Date | Agency | Company | Orphan |
---|---|---|---|
Sept. 10, 1998 | FDA | SANOFI AVENTIS US | |
Sept. 2, 1999 | EMA | Sanofi-aventis Deutschland GmbH |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Drug ineffective | 6652.86 | 14.64 | 18828 | 417845 | 1025937 | 62026412 |
Drug intolerance | 5071.13 | 14.64 | 8218 | 428455 | 300443 | 62751906 |
Contraindicated product administered | 4291.84 | 14.64 | 6310 | 430363 | 211338 | 62841011 |
Joint swelling | 3787.29 | 14.64 | 7487 | 429186 | 320179 | 62732170 |
Rheumatoid arthritis | 3725.76 | 14.64 | 6431 | 430242 | 247388 | 62804961 |
Synovitis | 3113.05 | 14.64 | 5015 | 431658 | 181903 | 62870446 |
Treatment failure | 3022.84 | 14.64 | 5123 | 431550 | 193920 | 62858429 |
Arthropathy | 2745.07 | 14.64 | 5396 | 431277 | 229396 | 62822953 |
Therapeutic product effect decreased | 2494.84 | 14.64 | 4633 | 432040 | 188554 | 62863795 |
Pemphigus | 2378.22 | 14.64 | 4411 | 432262 | 179315 | 62873034 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Drug ineffective | 2271.41 | 15.57 | 3421 | 60985 | 453330 | 34439195 |
Rheumatoid arthritis | 1754.08 | 15.57 | 1009 | 63397 | 37229 | 34855296 |
Joint swelling | 1666.66 | 15.57 | 1151 | 63255 | 58739 | 34833786 |
Drug intolerance | 1527.26 | 15.57 | 1089 | 63317 | 58481 | 34834044 |
Contraindicated product administered | 931.11 | 15.57 | 547 | 63859 | 20934 | 34871591 |
Synovitis | 796.59 | 15.57 | 427 | 63979 | 13639 | 34878886 |
Treatment failure | 775.38 | 15.57 | 661 | 63745 | 46036 | 34846489 |
C-reactive protein abnormal | 711.96 | 15.57 | 339 | 64067 | 8371 | 34884154 |
Arthralgia | 611.12 | 15.57 | 1109 | 63297 | 168932 | 34723593 |
Apparent death | 607.64 | 15.57 | 235 | 64171 | 3409 | 34889116 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Drug ineffective | 6120.21 | 13.77 | 14348 | 346154 | 1066565 | 78317321 |
Drug intolerance | 5601.12 | 13.77 | 6414 | 354088 | 257705 | 79126181 |
Joint swelling | 4634.96 | 13.77 | 6094 | 354408 | 282552 | 79101334 |
Contraindicated product administered | 3941.08 | 13.77 | 4177 | 356325 | 153361 | 79230525 |
Synovitis | 3863.70 | 13.77 | 4049 | 356453 | 146685 | 79237201 |
Rheumatoid arthritis | 3780.42 | 13.77 | 4679 | 355823 | 203791 | 79180095 |
Treatment failure | 3211.12 | 13.77 | 3902 | 356600 | 166584 | 79217302 |
Arthropathy | 2907.53 | 13.77 | 3785 | 356717 | 173326 | 79210560 |
Therapeutic product effect decreased | 2548.51 | 13.77 | 3411 | 357091 | 160452 | 79223434 |
Hand deformity | 1845.28 | 13.77 | 2311 | 358191 | 101608 | 79282278 |
None
Source | Code | Description |
---|---|---|
ATC | L04AA13 | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS IMMUNOSUPPRESSANTS IMMUNOSUPPRESSANTS Selective immunosuppressants |
CHEBI has role | CHEBI:35442 | antiparasitic drugs |
CHEBI has role | CHEBI:35475 | non-steroidal anti-inflammatory agent |
CHEBI has role | CHEBI:35610 | antineoplastic agents |
CHEBI has role | CHEBI:35705 | immunosuppressive agents |
CHEBI has role | CHEBI:37153 | protein serine/threonine phosphatase inhibitors |
CHEBI has role | CHEBI:38637 | tyrosine kinase inhibitors |
CHEBI has role | CHEBI:50266 | Prodrugs |
CHEBI has role | CHEBI:50908 | agente hepatotoxico |
CHEBI has role | CHEBI:68542 | DHODH inhibitor |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Psoriasis with arthropathy | indication | 33339001 | |
Rheumatoid arthritis | indication | 69896004 | DOID:7148 |
Inactive tuberculosis | contraindication | 11999007 | |
Agranulocytosis | contraindication | 17182001 | DOID:12987 |
Acute tuberculosis | contraindication | 25629007 | |
Immunosuppression | contraindication | 38013005 | |
Hepatic failure | contraindication | 59927004 | |
Chronic type B viral hepatitis | contraindication | 61977001 | |
Acute infectious disease | contraindication | 63171007 | |
Interstitial pneumonia | contraindication | 64667001 |
None
None
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 12.31 | acidic |
None
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Dihydroorotate dehydrogenase (quinone), mitochondrial | Enzyme | INHIBITOR | IC50 | 5 | CHEMBL | CHEMBL | |||
Sodium-dependent noradrenaline transporter | Transporter | Ki | 5.34 | DRUG MATRIX | |||||
Sodium-dependent dopamine transporter | Transporter | Ki | 5.64 | DRUG MATRIX | |||||
Cytochrome P450 1A2 | Enzyme | IC50 | 6.30 | DRUG MATRIX | |||||
Amine oxidase [flavin-containing] A | Enzyme | IC50 | 4.68 | DRUG MATRIX | |||||
Sodium/nucleoside cotransporter 1 | Transporter | Ki | 5.29 | DRUG MATRIX | |||||
Dihydroorotate dehydrogenase (quinone), mitochondrial | Enzyme | IC50 | 8.05 | CHEMBL | |||||
Dihydroorotate dehydrogenase (quinone), mitochondrial | Enzyme | IC50 | 7.52 | CHEMBL |
ID | Source |
---|---|
007642 | NDDF |
014643 | NDDF |
109143003 | SNOMEDCT_US |
11870 | MMSL |
1310520 | RXNORM |
28846 | MMSL |
365635 | MMSL |
386981009 | SNOMEDCT_US |
3899 | PUBCHEM_CID |
4021132 | VUID |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Arava | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0088-2160 | TABLET, FILM COATED | 10 mg | ORAL | NDA | 27 sections |
Arava | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0088-2160 | TABLET, FILM COATED | 10 mg | ORAL | NDA | 27 sections |
Arava | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0088-2161 | TABLET, FILM COATED | 20 mg | ORAL | NDA | 27 sections |
Arava | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0088-2161 | TABLET, FILM COATED | 20 mg | ORAL | NDA | 27 sections |
Arava | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0088-2162 | TABLET, FILM COATED | 100 mg | ORAL | NDA | 27 sections |
Arava | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0088-2162 | TABLET, FILM COATED | 100 mg | ORAL | NDA | 27 sections |
Leflunomide | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0955-1735 | TABLET, FILM COATED | 10 mg | ORAL | NDA AUTHORIZED GENERIC | 27 sections |
Leflunomide | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0955-1735 | TABLET, FILM COATED | 10 mg | ORAL | NDA AUTHORIZED GENERIC | 27 sections |
Leflunomide | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0955-1737 | TABLET, FILM COATED | 20 mg | ORAL | NDA AUTHORIZED GENERIC | 27 sections |
Leflunomide | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0955-1737 | TABLET, FILM COATED | 20 mg | ORAL | NDA AUTHORIZED GENERIC | 27 sections |